Enveric Biosciences issued patent for neuroplastogenic novel compounds

Enveric Biosciences (ENVB) announced the issuance of its 23rd patent from the United States Patent and Trademark Office for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental health disorders. The patent, U.S. Patent No. 12,428,408, titled, “Fused Heterocyclic Mescaline Derivatives,” covers a unique series of compounds, which are designed to target key serotonin receptors and drive neuroplasticity.